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Here	we	 report	 that	 the	 E3	 ubiquitin	 ligase	 STUB1	 ubiquitinates	 and	 destabilizes	
YAP1,	thereby	inhibiting	cancer	cell	survival.	Low	levels	of	STUB1	expression	were	
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a	major	public	health	problem	 throughout	 the	world,	 as	 it	 is	 the	
most	common	malignant	gastrointestinal	cancer,	especially	in	East	
Asia,1	 and	 causes	 12%	 of	 all	 cancer‐related	 deaths	 each	 year.2 
Over	 95%	 of	 gastric	 tumors	 are	 adenocarcinomas	 histologically	
classified	 as	 either	 intestinal	 or	 diffuse	 type.3	 Gastric	 cancer	 is	





As	 a	 key	 downstream	 effector,	 YAP1	 plays	 a	 key	 role	 in	
the	 Hippo	 pathway	 to	 control	 cell	 proliferation	 and	 growth.	











YAP1	 can	 be	 regulated	 by	 other	 posttranslational	 modification.	
Lats	and	CK1	coordinately	phosphorylate	YAP1	and	subsequently	















Here,	 we	 report	 that	 STUB1	 regulates	 GC	 cell	 proliferation	
and	 response	 to	 therapeutic	 drugs	 through	 the	 YAP1	 protein.	





low	 expression	 of	 STUB1,	 suggesting	 that	 the	 STUB1‐YAP1	 axis	
might	have	a	role	in	the	pathogenesis	of	GCs.
2  | MATERIAL S AND METHODS
2.1 | Cell culture, constructs, and Abs




ing	 analysis	 on	 1	 January	 2018,	 and	 confirmed	 by	 the	 National	
Infrastructure	 of	 Cell	 Line	 Resources	 of	 China.	 Expression	 plas‐
mids	 containing	 pCMV‐Flag‐STUB1,	 pCMV‐Myc‐STUB1,	 pCMV‐
Flag‐YAP1,	 and	 pCMV‐Myc‐YAP1	 were	 constructed	 as	 previously	








purchased	 from	 Cell	 Signaling	 Technology.	 Anti‐ub	 (sc‐8017)	 Abs	
were	purchased	from	Santa	Cruz	Biotechnology.	Antibodies	against	





were	 incubated	 for	24	hours	and	were	 then	 treated	with	mitomy‐
cin,	 cisplatin,	 or	 etoposide	 at	 the	 indicated	doses.	After	36	hours,	
the	96‐well	plates	were	read	in	an	Epoch2	microplate	reader	(BioTek	
Instruments).	The	cell	 survival	 ratio	 calculated	by	3‐(4,5‐dimethyl‐
thiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐	 2H‐
tetrazolium	assay	(Promega).
2.3 | Soft agar colony formation assays
The	indicated	GC	cells	were	plated	in	0.2%	(w/v)	agarose	with	a	base	










incubated	with	2	μg	of	 the	 indicated	Ab	 and	protein	A	or	 protein	
G	 Sepharose	 beads	 (Amersham	 Biosciences)	 for	 4	 hours	 at	 4°C.	




2.5 | Protein identification by mass spectrometry
Flag‐tagged	YAP1	or	empty	control	lentiviral	vector	was	transduced	
into	 MGC803	 cells	 in	 five	 15‐cm	 dishes.	 Immunoprecipitation	 of	
Flag‐YAP1	was	carried	out	as	described	above.	The	precipitated	pro‐
teins	were	eluted	with	3×	 flag	peptides.	The	eluted	 samples	were	
subjected	to	 in‐solution	 trypsin	digestion,	 followed	by	 liquid	chro‐
matography‐MS	analysis	and	protein	identification	was	undertaken	
using	 the	Mascot	 (version	 2.3.02)	 program	 and	 compared	 against	
the	UniProt	human	protein	database	(released	December	2014).	The	
following	search	parameters	were	used:	proteins	were	digested	by	
trypsin;	 2	 missed	 cleavages	 were	 allowed;	 carbamidomethylation	
was	set	as	the	fixed	modification,	whereas	oxidation	 (M)	was	con‐
sidered	 the	 variable	modification;	 an	 initial	 mass	 deviation	 of	 the	




2.6 | In vivo ubiquitination assay
This	 procedure	was	 carried	 out	 as	 previously	 described.21	 Briefly,	
cells	were	cotransfected	with	the	 indicated	plasmids	for	24	hours,	
and	were	treated	with	10	μmol/L	MG132	for	the	indicated	number	
of	 hours	prior	 to	harvesting.	Cells	were	 lysed	 in	RIPA	buffer	 con‐





collected	 at	 Clinical	 Medical	 College	 of	 Jinan	 University.	 Tissue	
sample	collection	was	approved	by	the	Internal	Review	and	Ethics	
Boards	 of	 Jinan	 University.	 Tissue	 microarray	 chips	 containing	
normal	 gastric	 tissue	 samples	 and	GC	 tumor	 tissue	 samples	were	
obtained	 from	 Shanghai	 OUTDO	 Biotech.	 Immunohistochemical	
staining	 and	 quantification	 were	 undertaken	 as	 described	 previ‐





2.8 | Athymic nude mouse tumor formation assay
Six‐week‐old	 female	 BALB/c	 nude	mice	were	 obtained	 from	 the	
Model	 Animal	 Research	 Center	 of	 Jinan	 University	 and	 housed	
under	pathogen‐free	conditions	in	the	animal	experiment	center	of	
Jinan	University.	A	total	of	1	×	106	MGC803	cells	stably	express‐















were	utilized	for	statistical	analyses	(*P < .05;	**P < .01).
Supplementary	materials	and	methods	in	Appendix	S1.
3  | RESULTS
3.1 | STUB1 is a YAP1 binding protein and 
destabilizes YAP1
The	 Hippo	 pathway	 has	 been	 implicated	 in	 suppressing	 tissue	
overgrowth	and	tumor	formation	by	 inhibiting	the	oncogenic	ac‐
tivity	of	YAP1.22	 The	dysregulation	of	 the	Hippo/YAP1	pathway	
is	 involved	 in	 cancer	 development.11,23,24	 However,	 the	 ubiqui‐
tin	 ligase	 that	 regulates	YAP1	protein	stability	 in	human	cancers	
remains	 largely	 unknown.	 To	 identify	 YAP1‐interacting	 ubiqui‐
tinases,	we	used	 cells	 stably	 expressing	Flag‐YAP1	 to	 undertake	
tandem	affinity	purification	and	mass	spectrometry	analysis;	sev‐
eral	proteins	were	identified,	 including	4	ubiquitin	ligases	(RNF4,	
WWP1,	 STUB1,	 and	CBX4),	 as	 YAP1	 interactors	 (Figure	 1A).	 To	
confirm	which	 ubiquitin	 ligase	 is	 responsible	 for	 YAP1	 degrada‐
tion,	we	first	examined	the	effects	of	these	4	ubiquitin	ligases	on	
YAP1	 expression.	We	 stably	 expressed	 shRNAs	 targeting	 these	
proteins	 individually	 in	 the	MGC803	 human	GC	 cell	 line	 (Figure	
S1A).	Only	one,	STUB1,	significantly	increased	endogenous	YAP1	
protein	 expression	 (Figure	 1B).	 Then	 we	 investigated	 the	 inter‐
action	between	STUB1	and	YAP1.	 Immunoblotting	assays	 in	 the	
coimmunoprecipitation	 experiment	 showed	 that	 endogenous	
YAP1	coimmunoprecipitated	with	endogenous	STUB1	(Figure	1C).	
STUB1	is	a	cochaperone	protein	and	E3	ubiquitin	ligase	that	regu‐




we	 coexpressed	 full‐length	 STUB1	with	 TPR	domain,	U‐box	 do‐
main,	and	the	middle	region	between	TPR	domain	and	U‐box	do‐
main	 fragments	 of	 STUB1	 in	 293T	 cells.	 Coimmunoprecipitation	
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and	western	blot	analysis	revealed	that	the	TPR	domain	of	STUB1	
interacted	with	YAP1	(Figures	1D	and	S1B).	Next,	we	investigated	




erone	Hsp90	 to	 facilitate	 TPR	 domain‐dependent	 ubiquitination	
















proximately	14	hours	 (Figure	S1G).	Taken	 together,	 these	 results	
indicate	that	STUB1	binds	and	destabilizes	YAP1	through	its	TPR	
domain,	which	needs	the	molecular	chaperone	Hsp90	to	facilitate.
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3.2 | STUB1 ubiquitinates YAP1 at K280 through 
K48‐linked polyubiquitination
We	 next	 examined	 whether	 STUB1	 regulates	 the	 level	 of	 YAP1	
ubiquitination	 in	cells.	As	shown	 in	Figure	2A,	STUB1	overexpres‐






found	 that	 the	T246M	mutation	of	 STUB1	did	 not	 increase	YAP1	
ubiquitination	(Figure	S2A),	suggesting	that	STUB	E3	ligase	activity	
is	indispensable	for	YAP1	ubiquitination.	To	test	whether	STUB1	can	

















F I G U R E  3  STUB1	regulates	cell	proliferation	and	tumor	growth	through	Yes‐associated	protein	1	(YAP1).	A,	B,	MGC803	cells	stably	
expressing	control	(Ctrl)	or	Flag‐STUB1	plasmids	together	with	or	without	YAP1	shRNAs	were	subjected	to	western	blotting	to	detect	
the	indicated	protein	levels.	YAP1‐regulated	target	transcription	genes	were	detected	by	quantitative	RT‐PCR.	Data	were	normalized	to	
the	β‐actin	mRNA	(mean	±	SD,	n	=	3).	*P < .05;	**P < .01.	C,	MGC803	cells	stably	expressing	Ctrl	or	Flag‐STUB1	plasmids	with	or	without	
Flag‐STUB1	plasmids	were	subjected	to	western	blotting	to	detect	the	indicated	protein	levels.	D,	Left:	colony	formation	abilities	of	the	cells	
generated	as	above	were	measured	after	2	wk.	Colony	numbers	of	cellular	clones	with	more	than	100	cells	was	measured	(mean	±	SEM	of	
3	independent	experiments).	Right:	statistical	analyses	were	carried	out	with	ANOVA.	*P < .05;	**P < .01.	E,	Left:	the	cells	described	above	
and	were	maintained	in	soft	agar	for	3	wk,	and	colony	number	per	field	was	determined.	Right:	statistical	analyses	were	carried	out	with	
ANOVA.	*P < .05;	**P < .01.	F‐H,	Cells	stably	expressing	Ctrl	or	shSTUB1	RNAs	with	or	without	shYAP1	RNAs	were	injected	into	athymic	
nude	mice,	as	described	in	the	Method	2.8.	Tumor	growth	was	measured	every	4	d.	Images	(G)	and	weight	(H)	of	xenograft	tumors	are	
shown	(mean	±	SD	of	6	mice).	All	of	the	statistical	analyses	were	carried	out	with	ANOVA.	*P < .05;	**P < .01
     |  3151TANG eT Al.




YAP1	 protein	 with	 ubiquitination	 modification,	 we	 used	 UbPred	
software	 (http://www.ubpred.org/).	 Five	 potential	 ubiquitination	
sites	at	 lysine	residues	were	found	 in	 the	YAP1	protein	 (Table	S1).	














K48R	mutant	 (Figure	 2E)	 and	 the	 cells	 transfected	 the	 plasmid	 of	





3.3 | STUB1 regulates cell proliferation and tumor 
growth through the YAP1 pathway





in	Figure	3B,	 silencing	YAP1	dramatically	decreased	 the	 transcrip‐
tion	of	ANKRD1, Cyr61,	and	CTGF	(column	1	vs	column	3)	and	STUB1	
overexpression	 also	 reduced	 the	 transcription	 of	 YAP1‐regulated	
target	genes	 (column	1	vs	column	2),	whereas	STUB1	overexpres‐
sion	did	not	show	any	additional	effect	in	YAP1‐depleted	cells	(col‐
umn	 3	 vs	 column	 4).	 These	 results	 suggest	 that	 STUB1	 regulates	
YAP1‐dependent	 transcription.	 To	 investigate	 the	 biological	 func‐
tion	 of	 STUB1	 in	 YAP1‐dependent	 cells,	 we	 evaluated	 prolifera‐
tion	and	anchorage‐independent	growth	of	STUB1‐overexpressing	
cells	 following	 the	 upregulation	 of	 YAP1	 expression	 in	 these	 cells	
(Figure	 3C).	We	 observed	 that	 YAP1	 overexpression	markedly	 in‐
creased	 both	 the	 proliferation	 (Figure	 3D,	 column	 1	 vs	 column	 2)	
and	 anchorage‐independent	 growth	 (Figure	 3E,	 column	 1	 vs	 col‐




STUB1	overexpression	 significantly	 reversed	 the	 effect	 of	 STUB1	
overexpression	 (Figure	 3C‐E,	 column	 3	 vs	 column	 4).	 Conversely,	
we	reduced	YAP1	expression	 in	MGC803	cells	with	STUB1	silenc‐
ing	 (Figure	S3A)	and	examined	cell	proliferation	and	anchorage‐in‐






in	 which	 the	 indicated	 numbers	 of	 MGC803	 cells	 were	 injected	
into	 athymic	 nude	 mice	 and	 tumor	 growth	 was	 monitored.	 Mice	
implanted	 with	 STUB1	 shRNA‐expressing	 MGC803	 cells	 showed	
increased	 tumor	 growth	 throughout	 the	 experiment	 compared	
with	 that	 in	 mice	 implanted	 with	 control	 shRNA‐expressing	 cells	
(Figure	3F).	At	23	days	after	tumor	cell	 implantation,	we	observed	
a	more	than	2.5‐fold	increase	in	the	volume	(Figure	3F)	and	a	2‐fold	






3.4 | STUB1 is downregulated in human gastric 
tumors and correlates with the YAP1 protein level
As	a	downstream	effector,	YAP1	plays	a	key	role	in	the	Hippo	path‐
way	 to	 control	 tissue	overgrowth	 and	 tumor	 formation.	YAP1	has	
primarily	 been	 reported	 as	 an	 oncoprotein;	 elevated	 expression	
and	nuclear	localization	of	YAP1	have	been	frequently	observed	in	
human cancers.7,33‐39	Posttranscriptional	and	posttranslational	reg‐
ulation	of	YAP1	have	been	 reported	 to	contribute	 substantially	 to	
the	development	of	human	cancer.10,40‐42	As	YAP1	plays	a	key	role	
in	human	cancer	development,	it	is	possible	that	in	human	cancers	




compared	with	normal	 gastric	 epithelial	GES‐1	 cells.	 Furthermore,	
low	STUB1	protein	 levels	 correlated	with	 increased	YAP1	expres‐
sion	 in	most	GC	 samples	 (Figure	 4B).	 To	 determine	 the	 relevance	
of	YAP1	 regulation	by	STUB1	 in	patients,	we	undertook	 immuno‐
histochemical	staining	of	YAP1	and	STUB1	(Figure	4C)	in	GC	tissue	
microarrays.	 Notably,	 downregulation	 of	 STUB1	 expression	 and	
high	YAP1	expression	were	observed	in	67.9%	(72/106)	and	74.5%	
(79/106)	 of	 gastric	 tumors,	whereas	 only	 27.3%	 (6/22)	 and	 31.8%	
(7/22)	 of	 normal	 mammary	 tissues	 showed	 low	 STUB1	 expres‐
sion	 and	 high	 YAP1	 expression	 (Figure	 4D),	 respectively,	 suggest‐
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3.5 | STUB1 regulates the response of GC cells to 
chemotherapy through YAP1
We	 found	 that	 STUB1	 negatively	 regulates	 the	 expression	 of	






or	 17‐AAG.	As	 shown	 in	 Figure	5A,	we	 found	 that	 17‐AGG	 inhib‐
ited	YAP1	degradation.	In	addition,	cells	treated	with	17‐AAG	were	
significantly	resistant	to	chemotherapy,	whereas	YAP1	knockdown	
promoted	 cellular	 chemosensitivity	 (Figure	 5B).	However,	 17‐AAG	
treatment	of	cells	with	stable	expression	of	YAP1	shRNAs	reversed	
the	 sensitivity	 to	 chemotherapy	 (Figure	 5B).	 Similarly,	 silencing	 of	
STUB1	 in	 SGC7901	 cells	 using	 2	 specific	 shRNAs	 significantly	 in‐
creased	the	YAP1	protein	levels	(Figure	5C)	and	increased	cell	resist‐
ance	to	mitomycin	C,	cisplatin,	and	etoposide	(Figure	5D),	whereas	




correlation	study	of	STUB1	and	YAP1	expression	level	in	GC.	Statistical	analyses	were	undertaken	with	the	χ2	test,	P < .001. R,	Pearson's	
correlation	coefficient





In	 summary,	we	 showed	 that	 STUB1	 interacts	with	 YAP1	 and	
promotes	its	ubiquitination,	ultimately	leading	to	YAP1	degradation	
























enzymes,	 E2	 ubiquitin‐conjugating	 enzymes,	 and	 E3	 ubiquitin	














reports	 have	 indicated	 that	 STUB1	 acts	 as	 a	 tumor	 suppressor	
because	it	induces	the	ubiquitination	and	degradation	of	several	
oncogenic	 proteins,	 such	 as	 mutant	 p53,51	 SRC‐3,52	 Smad3,53 




that	 this	 decrease	 might	 be	 associated	 with	 STUB1	 promoter	
methylation	 in	GC	 cells.60	 Thus,	 identifying	 novel	 substrates	 is	




why	 this	 E3	 ligase	 accounts	 for	 YAP1	 ubiquitination;	 several	
studies	have	reported	that	YAP1	undergoes	deubiquitinase‐me‐
diated	stabilization10,43,61	but	have	not	identified	which	E3	ligase	
mediates	 YAP1	 ubiquitination.	 The	mechanisms	 through	which	
E3	 ubiquitin	 ligases	 and	 deubiquitinases	 balance	 YAP1	 expres‐
sion	could	explain	why	the	activity	of	YAP1	 is	 tightly	regulated	
under	physiological	conditions,	whereas	elevated	YAP1	activity	
and/or	 overexpression	 has	 been	 observed	 in	 different	 cancer	
types.11
STUB1	 reportedly	 induces	 the	 degradation	 of	MST1,	 an	 up‐
stream	 inhibitor	 of	 YAP,	 in	 an	Hsp70‐interacting	 protein	 (CHIP)‐
dependent	manner	under	different	stresses	and	in	different	kinds	
of	cancer.62,63	This	 regulation	seems	to	be	the	opposite	of	YAP1	
activity,	 because	 we	 found	 that	 the	 interaction	 of	 STUB1	 with	






may	 target	YAP1	 for	ubiquitin	and	destabilization,	 thereby	 inhibit‐
ing	GC	growth	and	 tumor	progression.	The	 tumor	suppressor	 role	
of	 STUB1	was	 partially	 reversed	 by	 inhibition	 of	 YAP1	 activity	 in	




effect	 of	 YAP1	 inhibitors	 needs	 further	 testing.	 Furthermore,	 our	
findings	indicate	that	YAP1	ubiquitination	and	degradation	mediated	
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